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BACKGROUND AND INTRODUCTION 
 
Human papillomavirus (HPV) infection is a preventable yet common cause 
of morbidity and mortality with more than 14 million new cases per year in 
the U.S.1 HPV causes nearly all cervical cancers and many vaginal, vulvar, 
anal/rectum, penile, and oropharyngeal cancers.2,3 Approximately 1 in 4 
people in the U.S. are currently infected with HPV, and nearly 80% of people 
will develop HPV during their lifetime.1  
 
The HPV vaccine can prevent HPV infections that cause HPV-associated 
cancers. The Advisory Committee on Immunization Practices (ACIP) 
recommends initiation of the HPV vaccination series during early 
adolescence between ages 11 and12 years for both males and females.4 
Despite safety of the vaccine5, endorsement from professional 
organizations such as ACIP4, and a Healthy People 2020 HPV vaccine 
series completion goal of 80%,6 HPV vaccine uptake rates remain 
suboptimal. At the time of this study, national HPV vaccination initiation 
rates for ages 13 and 17 years were 53.5% and 65.4%, respectively.7  
 
Though evidence-based strategies have been developed to increase 
uptake of other vaccines,8 interventions aiming to increase HPV vaccine 
use have demonstrated limited impact.9,10 Evidence-based strategies to 
increase HPV vaccination rates include provider assessment and feedback 
, provider cues, patient reminders, and delivering bundled vaccine 
recommendations, but using any one of these strategies in isolation is less 
effective than applying multiple strategies.8 Theory- and evidence-based 
interventions can optimize effectiveness for individual and organizational 
change.11 The Adolescent Vaccination Program (AVP) is a theory- and 
evidence-based multilevel and multicomponent HPV vaccination 
intervention comprising sequential rollouts of system-level strategies. A 
recent quasi experimental study of the AVP, conducted in a large urban 
southwestern pediatric clinical network, demonstrated its success in 
significantly increasing HPV vaccination initiation and completion rates over 
a 3-year period (p ≤ 0.05).12 
 
Intervention Mapping (IM) is a systematic approach to planning theory- and 
evidence-based health promotion interventions.13 A recent systematic 
review demonstrated significant increase in the uptake of disease 
prevention behaviors associated with IM-based interventions when 
compared to placebo control groups.14 IM has been used to develop 
interventions for preventing cancer, including skin,15 lung,16 breast,17 and 
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cervical17-20 cancers. A recent study reported the use of IM to develop an 
HPV vaccination behavioral education intervention for parents of Hispanic 
adolescents.21 However, few applications of IM have been reported in the 
context of developing a multicomponent intervention that have comprised 
vaccination strategies targeting clinics, providers, and parents.21 The 
purpose of this paper is to describe the application of IM in the development 
of the theory- and empirically based AVP to increase HPV vaccination rates.  
 
METHODS 
 
Intervention Mapping 
 
IM is a stepped framework to guide the development of behavioral change 
interventions that enable developers to systematically apply social and 
behavioral science theories.22 The 6 steps of IM (Table 1) are to: 1) assess 
needs and develop a logic model of the problem, 2) develop matrices of 
behavioral change objectives for the program, 3) identify theory-based 
methods and practical applications to be applied in the program, 4) produce 
program components and materials, 5) plan for program adoption, 
implementation, and sustainability, and 6) plan for evaluation.13 This project 
was approved by The University of Texas Health Science Center at Houston 
Institutional Review Board (HSCSPH-14-0725).  
 
The Development Timeline 
 
Completion of the IM development process encompassed 2 years of 
activities (Table 1). The first 6 months of Year 1 involved development of 
the logic model of the problem (IM Step 1), defining program outcomes and 
objectives and matrices of change (IM step 2), and instituting the 
vaccination champion component to advocate for and mediate the 
implementation of the AVP within the clinic sites (as an advocate and 
mediator for the AVP). The remaining 6 months of Year 1 involved program 
planning, developing the AVP design document (IM Step 3), and initial 
rollout of the assessment and feedback strategies. Year 2 involved 
completing the full program prototype, including development cycles for 
each component followed by a formative evaluation with pilot testing of 
components (IM step 4). Plans for implementation and evaluation (IM Steps 
5 and 6) were consolidated during the period of AVP formative testing and 
were implemented from 2015 through 2018. 
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TABLE 1: Intervention Mapping (IM) Steps with Associated Tasks and AVP Deliverables 
Yr IM Steps IM Tasks Development Deliverables 
1 1. Assess need and 
develop a logic 
model 
of the problem 
• Establish and work with a planning group. 
• Describe the context for the intervention, including the 
population, setting, and community. 
• Conduct a needs assessment to create a logic model of the 
problem. 
• Clinic Provider Advisory Group 
• Literature review – evidence  table 
• PRECEDE Model 
 
2. Develop 
matrices of change 
objectives and a 
logic model of 
change 
• State expected outcomes for behavior and environment.  
• Specify performance objectives for behavioral and 
environmental outcomes. 
• Select determinants for behavioral and environmental 
outcomes. 
• Create a logic model of change. 
• Construct matrices of change objectives. 
• Matrices for provider outcome behaviors comprising 8 
performance objectives and 65 learning objectives. 
• Conceptual model for the AVP (model of change). 
3. Identify theory-
based methods 
and practical 
applications for 
program design 
• Generate program themes, components, scope, and 
sequence. 
• Choose theory- and evidence-based methods to create 
change. 
• Select or design practical applications to deliver change 
methods. 
• AVP design document comprising specifications including: 
content, design features, functionality, language, logistics of use 
and implementation in the clinic, orientation needs, and evaluation 
specifications.  
2 4. Produce 
program 
components and 
materials 
• Refine program structure and organization. 
• Prepare plans for program materials. 
• Draft messages, materials, and protocols. 
• Pretest, refine, and produce materials. 
• AVP Champion webinars (n=4). 
• AVP Champion Binders for each clinic. 
• Provider assessment and feedback reports. 
• Provider continuing education module. 
• EHR Best Practice Advisory for HPV vaccination. 
• Pediatric Wellness Registry for patient HPV vaccination reminders. 
• Pilot test protocols and results: 
• Manual of Procedures. 
• AVP component feasibility testing in advisory clinics.  
5. Plan for program 
adoption, 
implementation, 
and sustainability 
• Identify potential program implementers. 
• State outcomes and performance objectives for 
implementation. 
• Construct matrices of change objectives for implementation. 
• Design implementation interventions. 
• Processes and channels for deployment of AVP strategies. 
• Matrix of key stakeholders / gatekeepers for implementation. 
6. Plan for 
evaluation 
• Write effect and process evaluation questions. 
• Develop indicators and measures for assessment. 
• Specify evaluation design. 
• Evaluation Design Manual of Procedures, including:  
• Study hypotheses and protocols.  
• Measures for assessment. 
• Baseline and follow-up surveys for physicians and clinic staff. 
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IM STEP 1: LOGIC MODEL OF THE PROBLEM  
 
Step 1 comprised the following: establishing a planning group; conducting 
a needs assessment informed by the PRECEDE (Predisposing, Reinforcing 
and Enabling Constructs in Educational Diagnosis and Evaluation) planning 
model that outlines the factors associated with the problem; defining the 
context of the intervention in terms of population, setting, and community; 
and starting to implement program goals.13  
 
Task 1.1: Establish and work with a planning group 
 
Pediatric clinic population and setting. The AVP development involved 
collaboration with a large urban pediatric clinic network in the southwestern 
United States. The network comprised 51 pediatric practices in 5 counties 
(encompassing over 220 physicians and over 800 staff members), serving 
an estimated 20% of the pediatric population in these counties. Clinics 
varied in size, staff composition, patient demographics, and rates of 
initiation of HPV vaccination. Most clinics (97%) were certified by the 
National Committee for Quality Assurance (NCQA) and, where eligible, 
were NCQA-recognized medical homes. Five clinics were located in 
underserved areas and provided pediatric medical services for families who 
would otherwise receive limited or no health care due to low family income 
or lack of health insurance. The network participated in Healthcare 
Effectiveness Data and Information Set (HEDIS) accreditation.23 Patient 
demographics comprised white (59%), Hispanic (23%), African-American 
(13%), and Asian (5%). Most patients (73%) had commercial insurance; the 
rest had Medicaid (17%), Children’s Health Insurance Plan (CHIP) (6%), or 
no insurance (4%). Approximately 25% were eligible for the Vaccines for 
Children (VFC) program.  
 
Stakeholder Advisory Committee. The IM process recommends 
identification of key stakeholders, including experts, community members, 
potential implementers, leaders, and members of the population of interest, 
to form a planning group that guides intervention development.13 The AVP 
stakeholder advisory committee (SAC) comprised 3 researchers in HPV 
and cancer prevention, behavioral science, and intervention development, 
3 pediatricians, 1 pediatric information technologist, 1 data analyst, and 
leaders of the network, including the chief medical officer (CMO). The CMO 
identified a core of 6 advisory clinics with diverse geographic locations and 
mixed patient demographics and insurance payer base (private vs. public) 
to enable broad access to “frontline” providers for formative assessments 
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of the AVP components prior to implementation. The CMO, an 
administrator, and the project team held regular biweekly in-person 
meetings through the entire IM process to: plan and design components 
(including review content, assess functionality, flow, and the “look and feel” 
of AVP components); develop plans for seamless implementation (rollout) 
without disruption to standard operating procedures; and plan for evaluation 
activities. 
 
Task 1.2: Conduct a needs assessment to create a logic model of the 
problem 
 
The needs assessment identified clinic-, provider- and parent-level barriers 
to HPV vaccination to inform a logic model for HPV vaccination. This 
comprised the following: 1) rates of HPV vaccination among adolescents in 
the pediatric network compared to national rates; 2) perceived barriers, 
attitudes, and practices regarding clinic organization and provider-related 
factors impacting HPV vaccination; 3) perceived barriers, attitudes, beliefs, 
and needs regarding HPV vaccine among  parents of adolescents in the 
pediatric network, and 4) current national best practices regarding HPV 
vaccine promotion and strategies for incorporating HPV vaccination best 
practices into clinical settings. Quantitative and qualitative methods 
included literature review, analysis of cumulative vaccination data from the 
electronic health record (EHR), interviews with clinic leaders, focus groups 
with providers and staff in the 6 advisory clinics, and surveys with providers 
and staff across the network.  
 
Literature review 
 
Conducted in 2014 in collaboration with a research librarian, the literature 
review provided background on 1) current rates and burden of HPV 
infection, and 2) evidence-based strategies to increase vaccination rates 
and the clinical, behavioral, and psychosocial factors associated with their 
implementation. Inclusion criteria comprised articles published in peer-
reviewed journals, including review articles and surveys as well as practice 
guidelines. Abstracts, poster presentations, and editorial publications were 
excluded. Electronic publication databases comprised PubMed, EMBASE, 
and MEDLINE. The Community Preventive Services Task Force’s 
Community Guide8 provided a systematic review of the evidence of 
effectiveness of health promotion strategies that was foundational for this 
study. Strategies included provider assessment and feedback (A&F), 
provider cues, provider communication strategies (e.g., bundled 
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messaging), and patient reminders. Evidence tables were developed for 
expert review. The literature review provided information on national 
immunization recommendations to prevent HPV, system factors in clinic 
settings that facilitate provider recommendations for HPV vaccination 
initiation, and physician-level factors affecting parent decision making to 
accept HPV vaccination recommendations. Critical findings that informed 
the AVP are provided in Table 2. 
 
Analysis of cumulative vaccination data from the electronic medical 
record 
 
HPV vaccine initiation and completion rates were assessed for all patients 
ages 11-17 seeking care at the 51-clinic pediatric network from January 1 
through December 31, 2013. Among 92,735 patients over the 12-month 
period, overall HPV vaccine initiation was 49.4%. HPV vaccine initiation 
among girls was 54.0%, and among boys the rate was 44.9%. Overall 
completion rate for the HPV vaccine series was 24.2%. The completion rate 
was 30.3% among girls and 18.3% among boys. These rates fall far below 
the Healthy People 2020 goal of 80%. In the recommended 11- to 12-year 
age group, overall HPV vaccine initiation was 39.1%. For girls ages 11-12, 
HPV vaccine initiation was 42.0%; for boys it was 36.3%. Additionally, 44% 
of physicians had an HPV vaccine uptake rate less than 50%; 22% had an 
uptake rate less than 40%; and over 7% had an uptake rate less than 30%. 
In contrast, vaccination rates for tetanus, diphtheria, and pertussis (Tdap) 
and meningococcal vaccine (MCV) exceeded 91%. 
 
Interviews with clinic leaders in 5 advisory clinics  
 
Site leaders and practice managers and 14 clinic leaders were interviewed 
at 5 of the advisory clinics. Interviews were recorded and transcribed. 
Information was obtained on leadership roles and responsibilities, clinic 
workflow, current vaccine practices and protocols to adjust to changes in 
vaccine recommendations, barriers to HPV vaccination, and suggested 
strategies to increase HPV vaccination. The network’s expectation was for 
clinics to adhere to national standards (ie, ACIP), but there was significant 
variation in delivery of HPV recommendations between clinics and between 
physicians and medical assistants (MAs).  
 
Focus groups with providers and staff in the 6 advisory clinics 
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In-person focus groups were conducted with 78 staff members within the 
advisory clinics. Group size ranged from 9 to 18. Participants included 22 
pediatricians, 15 MAs, 14 nurses, 10 certified medical assistants (CMAs), 6 
front desk/reception staff, 5 practice managers, and 1 assistant director, 
clinical supervisor, physician assistant, X-ray technician, triage worker, and 
referral specialist. Each focus group was recorded and thematically 
analyzed. Focus group findings informed the AVP development and 
encompassed themes related to how the vaccine was introduced, provider 
barriers to recommending the vaccine, and parental barriers to the vaccine 
(Table 3).   
 
Surveys with providers and staff across the network 
 
Online surveys were distributed to all clinical staff at each clinic in the 
network (n=51) to assess baseline perceptions of HPV vaccine. The 30-
minute surveys were completed by clinical staff (nurses, physician 
assistants, and MAs) (n=375; response rate: 88.7%), practice managers 
(n=45; response rate: 90%), and physicians (n=134; response rate: 59.7%). 
The survey focused on physician experiences with the HPV vaccine and 
addressed organization and patient barriers that they encounter when 
vaccinating adolescents. The surveys comprised items with fixed format 
response options including 4-point Likert scales with varied response 
options (Strongly Agree/Strongly Disagree; Not at all a barrier/A major 
barrier, etc.).24 Providers were asked to select responses most 
representative of their experience. Analysis by the project team determined 
that lower initiation rates were mainly associated with physician concerns 
about parents’ negative perceptions about the HPV vaccine, the vaccine’s 
safety, its efficacy, and the financial burden the vaccine places on patients24 
(Figure 1). 
 
Task 1.3: Describe the context for the intervention including the 
population, setting, and community  
 
The AVP was developed for implementation in primary care clinics within a 
large pediatric network (previously described). The heterogeneity offered 
across the 51 clinics (size, location, time within the network) and the patient 
population (demographics, insurance status) provided an excellent test-bed 
for development. The priority environmental focus was the clinical 
organization and the provider. A parent-facing educational program is 
described elsewhere. Community sentiment regarding vaccination in 
general, and HPV vaccination in particular, were acknowledged as 
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important environmental influences in vaccine decision making (Figure 1). 
However, broader community influencers, while important, were outside the 
scope of the project.  
 
Table 2. Literature review key findings 
Key Finding Qualifications 
System factors are 
a major 
determinant of 
receiving HPV 
vaccination. 
Primary parental determinants of HPV vaccination 
initiation among adolescents were talking with a doctor, 
having enough time to discuss the vaccine, having a 
healthcare provider recommend it, and having a 
healthcare visit in the past year.25-28 Parents express a 
strong preference to receive information about HPV 
vaccination directly from trusted healthcare providers.29-31  
The research on 
provider attitudes 
and practices 
describes several 
sources of provider 
hesitancy to 
recommend or 
discuss the HPV 
vaccine with 
parents. 
Common sources of provider hesitancy include providers’ 
“perception that younger adolescents are less at risk of 
HPV so vaccination can be delayed,” providers’ 
perceptions of parental hesitancy and ambivalence, 
misunderstanding parental barriers to vaccination,22,32 and 
limited time with patients.33-38 Furthermore, delaying 
discussion of HPV vaccination leads to missed 
opportunities39 because younger adolescents (11-14 
years) are 3 times more likely to attend preventive visits 
than older adolescents.40 
Physician 
recommendation 
remains an 
important 
determinant in 
parents’ decision to 
vaccinate their 
child.29,41-43 
The CDC estimates that HPV vaccination initiation would 
reach over 90% if providers’ recommendations for HPV 
vaccination were similar to their recommendations for 
other adolescent vaccines.5 Commensurate with this is 
that providers convey vaccine recommendations 
consistent with evidence-based guidelines; provide 
accurate, evidence-based information about HPV and 
HPV vaccine; reassure patients of high vaccine safety 
due to ongoing postlicensure safety surveillance; and 
reinforce the message that the HPV vaccine is 
recommended despite not being required for school.  
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Table 3. Focus group key findings 
 
# Category Findings 
1 Introducing 
the HPV 
vaccine 
Providers tended to differentiate HPV vaccine from other 
vaccines recommended at the 11- to 12-year-old visit, 
presenting tetanus and diphtheria (Tdap) and 
meningococcal vaccine (MCV) as required for school but 
framing HPV as optional, either consciously or 
subconsciously. Most providers appeared reluctant to 
pursue the topic of HPV vaccination if the parent was 
hesitant or resistant, especially for younger children. 
Practices varied on whether the physician or clinical 
support staff first introduced the HPV vaccine and whether 
the parent received the Vaccine Information Statement 
(VIS) at the beginning or the end of the visit.  
2 Provider 
barriers 
Providers, particularly MAs, stated their own concerns as 
insufficient knowledge about HPV and HPV-related 
diseases, the perception that there was no immediate need 
to vaccinate younger adolescents, and not understanding 
the rationale for HPV vaccination starting at age 11.  
3 Parental 
barriers 
Providers stated that the most frequent concerns 
expressed by parents were not knowing or understanding 
the diseases the HPV vaccine prevents, wanting to wait 
until the child was older (child not having sex), wanting to 
wait until more was known about the long-term effects 
(vaccine was too new), and wanting to think about it or 
discuss it with their spouse.  
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Figure 1. Logic model of the problem: Health care provider determinants of provider behaviors and 
parent outcomes 
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Task 1.4: State program goals 
 
The goal of the AVP was to use a multicomponent strategy to enable clinics 
to meet national metrics for HPV vaccination initiation and completion. This 
entailed enabling clinicians, providers, and staff members to adopt and 
implement evidence-based strategies to increase HPV vaccination. 
Respective organizational, provider/staff, and patient goals for the AVP 
included the following: 
 
1. Primary care pediatric clinics that adopt and implement the AVP will 
demonstrate a significant increase in HPV vaccination initiation and 
completion rates in the clinic during implementation compared to rates 
prior to implementation. 
 
2. Providers and staff who adopt and implement AVP-related behaviors 
within their clinic will demonstrate a significant increase in their patients’ 
HPV vaccination initiation and completion rates during implementation 
compared to rates prior to implementation. 
 
3. Children who attend clinics implementing the AVP will be more likely to 
receive the HPV vaccination after implementation than they were prior 
to implementation of the AVP.  
 
IM STEP 2: PROGRAM OUTCOMES AND OBJECTIVES – LOGIC 
MODEL OF CHANGE 
 
Step 2 comprised the following: identification of expected outcomes, 
performance objectives, and determinants of the behavior and environment; 
the development of matrices of change objectives; and the construction of 
a logic model of change for the AVP.13 This step enabled the triangulation 
of data obtained in Step 1 (from theory, empirical findings, and participant 
involvement) to inform a logic model of change. 
 
Task 2.1: State expected outcomes for behavior and environment 
 
Expected Behavioral Outcomes. The AVP was designed to positively 
impact the adoption and implementation of evidence-based strategies to 
increase HPV vaccination rates in primary care pediatric clinics. The 
expected behavioral outcome was that pediatricians will vaccinate eligible 
patients against HPV in accordance with ACIP guidelines. Targeted health 
and quality-of-life outcomes included impact on health status (decreased 
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sexually transmitted infection [STI] and cancer incidence, reduced 
hospitalizations), functional status (increased future productive days at 
work, enhanced functioning and relationships), and long-term impacts 
(reduced societal cost of years of life lost, medical care, and long-term care 
costs) (Figure 2).  
 
Expected Environmental Outcomes. The AVP was designed to enable 
clinics to adopt evidence-based strategies (AVP champions, assessment 
and feedback, provider education, provider cues, and patient reminders) as 
usual practice.  
 
Task 2.2: Specify performance objectives for health-promoting 
behavior and environmental outcomes 
 
Performance objectives (PO) for adoption and implementation of 
evidence-based HPV vaccination strategies in the AVP  
 
Performance objectives comprised the following: collaborate with the 
clinic’s champions on immunization status updates and strategies regarding 
HPV vaccination (PO.1); review quarterly assessment and feedback reports 
for HPV vaccination (PO.2); coordinate with clinical support staff to ensure 
that consistent messaging is delivered to patients regarding HPV 
vaccination (PO.3); check vaccine eligibility (Forecaster database) at every 
encounter to identify if patient is eligible for vaccination (PO.4); deliver 
strong recommendation for HPV vaccination to all eligible patients at time 
of visit (PO.5a); bundle the HPV vaccine recommendation with other 
vaccines when the patient is due for other vaccinations at the same visit 
(PO.5b); determine specific patient/parent concern if they express vaccine 
hesitancy (PO.6); communicate tailored messages to address specific 
patient/parent concerns (PO.7); and remind patients to schedule follow-up 
HPV vaccine dose(s) before leaving the office (PO.8) (Figure 2). 
 
Task 2.3: Select determinants for behavioral and environmental 
outcomes 
 
Findings from the empirical literature, relevant theory (ie, Social Cognitive 
Theory,44 Theory of Reasoned Action,45 Health Belief Model46) and prior 
formative research (Task 1.2 above) informed selection of behavioral 
determinants. These comprised knowledge, self-efficacy, outcome 
expectations, skills, and normative beliefs as important and changeable for 
providers to perform AVP-related performance objectives (Table 4).  
12
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Figure 2: Logic Model of Change for AVP   
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Table 4. Health care provider matrix of performance objectives, determinants, and change objectives.  
Behavioral outcome: Physicians will vaccinate eligible patients against HPV in accordance with ACIP guidelines 
Performance 
Objectives 
Behavioral Determinants* 
Knowledge Skills and Self-efficacy Outcome Expectations Normative Beliefs 
PO.1. Collaborate 
with clinic’s 
champion on AVP 
strategies to 
promote HPV 
vaccination 
K.1a: Identify the designated AVP 
champions in his/her clinic 
K.1b: Describe the role of AVP 
champions as mediators for strategic 
rollout of 4 strategies* in clinics  
SSE.1a: Demonstrate ability to 
collaborate with clinic champion on 
strategies* to promote HPV 
vaccination 
SSE.1b: Express confidence in ability 
to collaborate with clinic champion on 
strategies* to promote HPV 
vaccination 
OE.1: Expect that collaborating with 
clinic’s champion on HPV vaccine 
promotion strategies will improve 
personal and clinic-level HPV 
vaccination rates 
NB.1:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the network’s expectation for 
optimal physician performance 
 
PO.2. Review 
quarterly 
assessment and 
feedback report for 
HPV vaccination 
K.2a: Identify when and how A&F 
reports will be delivered 
K.2b: Describe the content of the A&F 
reports 
K.2c: Recognize that A&F is one of 
the most effective strategies to 
promote vaccination 
SSE.2a: Demonstrate ability to state 
personal and clinic-level vaccine rates 
from a quarterly A&F report 
SSE.2b: Demonstrate ability to state 
personal HPV vaccination goal for the 
following quarter  
SSE.2c: Express confidence in ability 
to interpret A&F reports 
OE.2a: Expect that reviewing A&F 
reports will allow his/her clinic and 
staff to track progress toward HPV 
vaccination goals  
OE.2b: Expect that reviewing A&F 
reports will improve personal and 
clinic-level HPV vaccination rates  
NB.2:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
PO.3. Coordinate 
with clinical support 
staff to ensure 
consistent 
messaging is 
delivered to 
patients regarding 
HPV vaccination 
K.3a: Describe the difference 
between consistent and inconsistent 
messaging about HPV vaccination in 
a clinic setting 
K.3b: Recognize that inconsistent 
messaging about HPV vaccination 
occurs in clinics 
K.3c: Recognize that inconsistent 
messaging about HPV vaccination 
SSE.3a: Demonstrate ability to 
communicate with clinical staff about 
consistent HPV vaccine messaging** 
SSE.3b: Express confidence in ability 
to communicate with clinical staff 
about consistent HPV vaccine 
messaging** 
OE.3a: Expect that delivering 
consistent messaging from all clinical 
staff to patients will reduce 
patient/parent resistance  
OE.3b:  Expect that delivering 
consistent messaging from all clinical 
staff to patients will improve personal 
and clinic-level HPV vaccination rates 
NB.3:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
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can lead to parental vaccine 
hesitancy  
PO.4. Check 
forecaster at every 
encounter to 
identify if patient is 
eligible for 
vaccination 
K.4a: List ACIP eligibility criteria for 
HPV vaccination in adolescents 
K.4b. Describe functions of 
Forecaster 
K.4c: Recognize that patients are less 
likely to come back to doctor after age 
13  
SSE.4a: Demonstrate ability to check 
forecaster in a timely manner to 
determine patient vaccinations status  
SSE.4b: Express confidence in ability 
to check Forecaster in a timely 
manner  
OE.4a: Expect that identifying eligible 
patients at every encounter will 
reduce missed opportunities to 
vaccinate  
OE.4b: Expect that identifying eligible 
patients at every encounter will 
improve personal and clinic-level 
HPV vaccination rates 
NB.4: Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
PO.5. Deliver 
strong 
recommendation 
for HPV 
vaccination to all 
eligible patients at 
time of visit 
K.5a: Recognize HPV vaccination is 
an effective cancer prevention tool 
K.5b: Recognize HPV vaccination is 
safe and recommended by medical 
organizations with the same strength 
as other adolescent vaccines  
K.5c: Describe components of a 
strong HPV vaccine recommendation 
SSE.5.1: Demonstrate ability to 
deliver strong HPV vaccine 
recommendation  
SSE.5.2: Express confidence in ability 
to deliver strong HPV vaccine 
recommendation  
OE.5a: Expect that delivering a 
strong HPV vaccine recommendation 
to all eligible patients will reduce 
patient/parent resistance 
OE.5b: Expect that delivering a 
strong HPV vaccine recommendation 
to all eligible patients will improve the 
likelihood of patients initiating the 
HPV vaccine series 
NB.5a:  Recognize that vaccinating 
all eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
NB.5b: Recognize that HPV 
vaccination is widely endorsed by 
medical organizations and other 
physicians as a safe and effective 
cancer prevention tool  
NB.5c: Recognize that physicians 
tend to overestimate the level of 
hesitancy parents have about the 
HPV vaccine  
PO.5a. Bundle 
HPV vaccine 
recommendation 
with other vaccines 
when patient is due 
for other 
vaccinations at the 
same visit 
K.5a: Describe the difference 
between a bundled HPV 
recommendation and one that singles 
out HPV from other vaccines 
K.5b: Describe key elements of a 
bundled HPV vaccine 
recommendation  
SSE.5a.1: Demonstrate ability to 
deliver bundled HPV vaccine 
recommendation  
SSE.5a.2: Express confidence in 
ability to deliver bundled HPV vaccine 
recommendation 
OE.5a: Expect that bundling HPV 
vaccine recommendation with other 
vaccinations will reduce 
patient/parent resistance  
OE.5b: Expect that bundling HPV 
vaccine recommendation with other 
vaccinations will improve the 
NB.5a:  Recognize that vaccinating 
all eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
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likelihood of patients initiating the 
HPV vaccine series 
PO.6. Determine 
specific 
patient/parent 
concern if they 
express vaccine 
hesitancy 
K.6a: List common parental concerns 
related to vaccine hesitancy  
 
SSE.6a: Demonstrate ability to 
identify specific patient/parent 
concerns related to HPV vaccination 
SSE.6b: Express confidence in ability 
to identify specific patient/parent 
concerns 
OE.6a: Expect that identifying specific 
patient/parent concerns will save time 
in vaccine discussions  
OE.6b: Expect that identifying specific 
patient/parent concerns will improve 
the likelihood of patients initiating the 
HPV vaccine series 
NB.6:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
PO.7. 
Communicate 
tailored message to 
address specific 
patient/parent 
concern 
K.7: Describe key talking points to 
address common parental concerns 
related to vaccine hesitancy 
SSE.7a: Demonstrate ability to deliver 
tailored message to patients/parents 
about their specific vaccination 
concerns 
SSE.7b: Express confidence in ability 
to deliver tailored message to 
patients/parents about their specific 
vaccination concerns 
 
OE.7a: Expect that delivering tailored 
messages to address patient/parent 
vaccination concerns will save time in 
vaccine discussions  
OE.7b: Expect that delivering tailored 
messages to address patient/parent 
vaccination concerns will improve the 
likelihood of patients initiating the 
HPV vaccine series 
NB.7:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s 
expectation for optimal physician 
performance 
PO.8. Remind 
patients to 
schedule 2nd and 
3rd HPV vaccine 
dose before leaving 
the office 
K.8a: Describe CDC’s recommended 
dosing schedule for the HPV vaccine 
series 
K.8b: Recognize the importance of 
series completion for optimal cancer 
prevention benefits 
SSE.8a: Demonstrate ability to 
remind patients to schedule 2nd and 
3rd vaccine dose before leaving the 
office 
SSE.8b: Express confidence in ability 
to remind patients to schedule 2nd and 
3rd HPV vaccine dose before leaving 
the office 
OE.8: Expect that reminding patients 
to schedule their 2nd and 3rd HPV 
vaccine dose will improve the 
likelihood of patients completing the 
HPV vaccine series 
NB.8:  Recognize that vaccinating all 
eligible patients against HPV in 
accordance with ACIP guidelines is 
part of the clinic network’s  
expectation for optimal physician 
performance 
*Strategies include: Immunization Champions, Assessment and Feedback (A&F), CME, and Provider Cues. 
**Communication with clinical staff should include ensuring they: present HPV vaccination with the same importance as other vaccines, bundle the introduction of HPV vaccine with 
other vaccines when appropriate, and understand that physicians are looking to increase their vaccination rates and thus expect to vaccinate all eligible patients against HPV when 
they come in for a visit. 
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Task 2.4: Construct matrices of change objectives 
 
Matrices were developed that cross-referenced behavioral performance 
objectives with psychosocial determinants to produce change objectives 
(Table 4). The resulting cells of each matrix contained change objectives. 
Change objectives described the criteria for which a specific determinant 
(eg, self-efficacy) could positively influence a specific performance 
objective. 
 
Task 2.5: Create a logic model of change 
The resultant logic model provided an encapsulated understanding of the 
functional components required by the AVP to impact the provider 
behaviors (Figure 2). 
 
IM STEP 3: PROGRAM PLAN 
 
Step 3 comprised the following: the generation of the AVP’s scope and 
sequence, the choice of theory- and evidence-based methods, and the 
design of practical applications to deliver change methods. Step 3 tasks 
were informed by evidence tables constructed in Step 1 and from the 
research team’s collective academic and clinical experience. Regular 
planning group meetings and brainstorming informed the AVP plan.   
 
Task 3.1: Generate program themes, components, scope, and 
sequence 
 
The theoretical framework for the AVP is based in Social Cognitive 
Theory,44 Theory of Reasoned Action,45 the Health Belief Model,46 clinical 
guidelines for HPV vaccination,4 and empirical evidence drawn from the 
review of literature on evidence-based strategies to increase HPV 
vaccination rates. The development challenge was to meet both the clinic 
provider and staff needs in a format for easy institutionalization within 
clinics. Components. Intervention components comprised the following: 
immunization champions, A&F reports, provider online continuing education 
(CE), EHR provider cues, and parent vaccination reminders (Figure 3). 
Design documents and schematics were produced by the project team, 
reviewed by stakeholders, and piloted with providers in situ in advisory 
clinics prior to implementation (detailed in task 4.4 below).  Scope. AVP 
scope was defined by evidence-based strategies shown to be efficacious in 
increasing HPV vaccination rates in clinic settings. Provider interviews 
(described previously) and observation of clinic workflow suggested the 
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scope and sequence of the AVP functions and rollout (Figure 3) and is 
described in detail in step 4 below. Theme. The AVP was designed as a 
sequential rollout of strategies with minimal disruption to clinic flow. The title 
Adolescent Vaccination Program (AVP) was initially a working title during 
development. Despite having broader connotations beyond HPV, the name 
stuck during field testing.    
 
Task 3.2: Choose theory- and evidence-based change methods 
 
Individual Behaviors 
 
Theoretically and empirically based methods varied for each AVP 
component. Methods included assessment of HPV vaccination behaviors, 
feedback on HPV vaccination rates, reinforcement for behavioral 
successes, goalsetting to address improvement in HPV vaccination rates, 
advance organizers and cues for real-time alerts to instigate HPV 
vaccinations, self-monitoring of HPV vaccination behaviors, facilitation and 
linkage to skills training, and technical support as needed (Table 5). The 
project team selected methods based on empirical evidence for their use to 
impact the target determinants (exemplified in Tables 1 and 2).13  
 
Clinic Environment 
 
Quality-of-Care Measures. Published quality-of-care measures for clinical 
practice were consulted to determine context of use for the AVP. The AVP 
was aligned with the Healthy People 2020 Guideline and HEDIS 
benchmarks of 80% vaccination for eligible patients. HEDIS metrics for 
quality of care have been adopted as best-practice standards for U.S. 
clinics.23 Clinic Task Analysis. Task analysis was conducted in each of the 
participating clinics to examine data flow within the clinic, provider decision 
making, interaction points between the patient and provider or clinic staff, 
and interaction with the EHR. This identified logical opportunities for 
adoption and implementation of evidence-based strategies (Figure 4). 
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Figure 3. AVP: System rollout of evidence-based strategies into network clinics 
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Table 5. Example of methods and practical applications used in AVP to impact determinants for vaccination 
behavior 
 
Behavioral outcome: Physicians will vaccinate eligible patients against HPV in accordance with ACIP guidelines 
Performance objective: PO2. Review quarterly assessment and feedback (A&F) report for HPV vaccination 
 
# Objective Method Practical Application 
KNOWLEDGE 
K.2a: Identify when and how A&F reports will be delivered 
K.2b: Describe the content of the A&F reports 
K.2c: Recognize that A&F is one of the most effective 
strategies to promote vaccination 
 
  
Skill building and guided 
practice 
Chunking 
Tailoring 
Feedback 
Consciousness raising 
Champions receive one champion binder to hold A&F reports, newsletters, and 
information about webinars for providers to access. 
Champions send logs recording each provider’s receipt of the A&F report back 
to the project team.  
Champions educate providers about the effectiveness of A&F reports. 
Providers engage in CEs, which provide education regarding the effectiveness of 
A&F reports.  
SKILLS AND SELF-EFFICACY 
SSE.2a: Demonstrate ability to state personal and clinic-level 
vaccine rates from a quarterly A&F report 
SSE.2b: Demonstrate ability to state personal HPV vaccination 
goal for the following quarter  
SSE.2c: Express confidence in ability to interpret A&F reports 
 
Elaboration 
Reinforcement 
Goal setting 
Tailoring  
A&F reports colorful images, graphs, and tailored reports to display information 
about clinic- and provider-level vaccination rates. 
Clinic-level reports provide vaccination rates for each provider in the clinic and 
the clinic’s rate in comparison to all other network clinics.  
Provider-level reports include messaging and badges to encourage providers 
who have met ACIP vaccine and initiation and completion goals to continue their 
strong work in cancer prevention.  
Provider-level reports inform providers when they have not met their vaccination 
prevention and completion goals and provide the number of additional 
vaccination initiations and completions needed to meet ACIP goals in the coming 
quarter.  
OUTCOME EXPECTATIONS  
OE.2a: Expect that reviewing A&F reports will allow his/her 
clinic and staff to track progress toward HPV vaccination goals  
OE.2b: Expect that reviewing A&F reports will improve 
personal and clinic-level HPV vaccination rates 
Self-assessment 
 
 
Quarterly A&F reports are stored in the champion binder for tracking provider 
and clinic vaccination rate progress from quarter to quarter. 
 
 NORMATIVE BELIEFS 
NB.2:  Recognize that vaccinating all eligible patients against 
HPV in accordance with ACIP guidelines is part of the clinic 
network’s expectation for optimal physician performance  
Persuasive communication  
Information about others’ 
approval 
Physician newsletters from the clinic network director provides messaging 
regarding the network’s vaccination initiation and completion goals.  
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FIGURE 4. Clinic task analysis flow. 
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Task 3.3: Select or design practical applications to deliver change 
methods 
 
Practical applications were selected to operationalize the theory-based 
change methods in ways that fit the population and setting. The AVP was 
designed for easy adoption by clinic providers and staff. The champions 
provided an acknowledged point of contact, an “embedded” advocate for 
the AVP, and a mediator for delivery of AVP strategy rollout.  Clinic 
information technology was used to provide online CE training (through 
HealthStream, the online portal for provider education within the clinical 
network), provider cues for HPV vaccination eligibility (through Epic), and 
patient reminder notifications (through MyChart). This is discussed further 
in Task 5.3. 
 
IM STEP 4: PROGRAM PRODUCTION  
 
Step 4 comprised refinement of the AVP’s structure and organization, 
planning for program materials, drafting of messages and materials, and 
pretesting, refinement, and production of materials.13 
 
Task 4.1: Refine program structure and organization 
 
Evidence-based provider-level strategies, previously described in the 
empirical literature (step 1), informed the development and adaptation of 
AVP component strategies. The AVP included an implementation strategy 
(AVP champions embedded in each clinic) and 4 evidence-based 
interventions (goal-based A&F, provider education, provider reminders, and 
tailored patient reminders) that provide strong evidence when used in 
combination. A description of each strategy and its implementation are 
described below.   
 
AVP champions 
 
Immunization champions are an implementation strategy. They serve as 
advocates of the AVP and as mediators for rollout of evidence-based 
strategies. They distribute A&F reports to physicians (physician report) and 
clinic staff (nurses, physician assistants, and MAs) and clinic managers 
(clinic level report), promote CE completion, and announce implementation 
of provider reminders. Two AVP champions were selected per clinic and 
typically comprised 1 site leader or physician and 1 clinical supervisor or 
clinic staff member. Champion recruitment comprised an email sent from 
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the clinic network’s CMO requesting AVP champions be instituted. 
Champions participated in four 30-minute lunchtime webinar trainings that 
occurred prior to each strategy rollout. Webinars comprised the following: 
1) an overview of project goals and objectives; 2) evidence-based 
strategies; 3) how to implement and monitor intervention strategies; 4) 
resources and technical support from the project team; and 5) Q&A. 
Webinars were conducted live and recorded for later use. AnyMeeting, an 
online platform for webinar delivery, was used to host the webinars. The 
same physician who narrated the provider education modules recorded the 
narration for champion webinars. Champions received a binder to store 
resources to assist AVP implementation. The binders included an overview 
of the AVP, contact lists of the project team, a directory of all champions 
within the clinic, an introduction from the CMO, A&F reports from each 
quarter, printed webinars (including PowerPoint slides), fact sheets, 
information about future webinars and initiatives, and resources (Qlikview 
tutorial and CDC HPV tip sheet for health care providers, promotional flyers, 
and tracking forms).   
 
Assessment and Feedback reports 
 
A&F reports were designed for physicians, clinic managers, and clinic staff 
to evaluate their past and current vaccine rates (Figure 5). Reports provided 
to clinic staff and practice managers contained clinic-level data (clinic 
vaccination rates) while reports provided to physicians also contained 
personalized information on vaccination performance and vaccination 
goals. Content of the physician reports was particularly informed by CDC’s 
Assessment, Feedback, Incentives, and Xchange (AFIX) program 
strategies for improving HPV vaccination. SAC feedback guided iterative 
development of the report including data presented, layout, colors, and 
messaging. A&F reports comprised the following: 1) vaccine trends (Tdap, 
MCV, HPV) across the network clinics, 2) quarterly vaccination rates for 
each clinic, and 3) quarterly vaccination rates for each provider. Metrics 
included percentage of eligible patients who have ever received vaccines 
for Tdap, MCV, or HPV, and percentage of patients who have completed 
the HPV vaccine series. Also included were tailored text summaries for 
each provider comprising either a target goal (ie, “To meet the national goal 
of 80% HPV vaccination over the next year, you need to initiate at LEAST 
___ patients per quarter”) or a reinforcement if the provider reached 80% 
HPV series initiation, 60% series completion, or both (ie, “WOW! Thank you 
for your OUTSTANDING work in Cancer Prevention! Keep up the good 
work!”). Providers who initiated or completed the HPV series equal to or 
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above these goals also received a badge of recognition. Clinics meeting the 
80% initiation criterion also received a badge stating: “All doctors >80% 
HPV Series Initiation.” Qlikview, an application within the network’s EHR 
system, was used to generate and refine monthly data by the project team 
statistician, who translated this into graphic displays for inclusion in the 
quarterly A&F reports. The team delivered the reports to clinic champions, 
who distributed them to each physician within their clinic in February, May, 
August, and November. 
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Figure 5. Assessment and feedback reports 
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Figure 5 (continued) 
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Provider education 
 
A comprehensive online continuing education (CE) for doctors (continuing 
medical education, CME) and nurses (continuing nursing education, CNE) 
was developed for network pediatricians, nurses, and clinical staff (Figure 
6). CE objectives were to: 1) inform providers about emerging HPV 
vaccination guidelines and new initiatives being implemented by the 
network, and 2) provide skills to help providers engage with and motivate 
patients/parents to adhere to vaccination schedules. Content comprised the 
following: 1) ethical principles in HPV vaccination; 2) about HPV; 3) latest 
guidelines on the HPV vaccination; 4) evidence-based strategies for 
increasing HPV vaccination; and 5) recommended communication 
strategies (e.g., assertive bundled recommendations) and rolling with 
resistance when parents are vaccine-hesitant. A network physician 
provided voice narration. The finalized CE was reviewed by the SAC and 
accepted by the accreditation board of the network for credit approval. Clinic 
network leadership approved the HPV training module for 1 hour of ethics 
CE credit. A medical ethicist collaborated with the team to incorporate ethics 
principles (e.g., the principle of justice encompasses the need to 
recommend HPV vaccination equally and universally to all eligible patients). 
Ethics credit provided further incentive. Provider CE was implemented in 
the form of a self-paced CE module delivered through HealthStream, an 
online content management system. 
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Figure 6. Provider continuing education 
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Provider reminders 
 
Provider behavioral cues comprised Best Practice Advisory (BPA) alerts to 
enable providers and staff to easily identify age-eligible patients due or 
overdue for HPV vaccination. The BPAs were developed in collaboration 
with the clinic network’s EHR team, including the physician developer of 
pre-existing asthma and flu BPAs, and informed by CDC guidelines (Figure 
7). The algorithm for the alert system comprised the following: 1) alert for 
first HPV vaccine (HPV-1) if patient is a female 12-26 years of age or male 
12-21 years of age AND has no prior HPV vaccination; 2) alert for second 
HPV dose (HPV-2) if patient is female or male 12-26 years of age AND 
received HPV-1 before 15 years of age AND 6 months or more have passed 
since HPV-1 vaccine OR patient is female or male 12-26 years of age AND 
received HPV-1 at 15 years of age or older AND 1 month or more has 
passed since HPV-1; and 3) alert for third dose of HPV vaccine (HPV-3) if 
patient is female or male 12-26 years of age AND received HPV-1 at 15 
years of age or older AND 4 months or more have passed since HPV-2 
vaccine. While ACIP recommends routine HPV vaccine initiation beginning 
at age 11, the network preferred to commence the BPA alerts beginning at 
age 12. BPA alerts commenced at age 12 because HPV vaccination was 
already considered standard care for the 11-year-old visit, when the vaccine 
is included in the order set. The BPAs were added to the Epic system and 
modified to reflect updates in CDC guidelines, most notably in 2017 when 
the 2-dose schedule for adolescents under 16 years of age was released. 
During clinical encounters with a patient who is due or overdue for HPV 
vaccination, an alert appears in the patient’s EHR, prompting the provider 
to initiate HPV vaccination. The BPA system sends alerts during both well-
child and sick visits. Alerts contain a link to order the vaccine and multiple 
response options for case records: done, ordered, patient declined, patient 
not eligible, discussed, or not addressed. 
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Figure 7. Provider reminders 
 
 
 
 
 
Patient reminders  
 
The American Academy of Pediatrics (AAP) reminder and recall systems 
guidelines informed the development of reminder messages for parents 
with vaccine-eligible children (Figure 8). Messages were developed to 
remind parents to Initiate the HPV vaccine and to schedule 2nd and, as 
appropriate, 3rd doses. Messages followed existing formatting standards 
used by the network and were reviewed for content by the SAC before being 
incorporated into an automatic messaging system. Patients who were 
identified as 10 years and 11 months of age through 17 years and vaccine 
eligible were flagged to receive targeted reminders. This was done using an 
existing Pediatric Wellness Registry integrated within the network’s Epic 
and MyChart systems. Automated messages were sent 1 month before the 
child’s HPV vaccine due date. Parents were able to see their upcoming due 
date for their child’s HPV immunization on the Preventive Care page in 
MyChart, the patient-facing application of the Epic EHR. 
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FIGURE 8. Patient reminders 
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Task 4.2: Prepare plans for program materials 
 
AVP design documents provided a blueprint of the functional specifications 
and rollout sequence of each strategy (Figure 3). Project team conference 
calls and face-to-face meetings provided iterative review and feedback on 
the design. Design documents described content, design features, 
functionality, language, logistics of use and implementation in the clinic, 
orientation needs, and evaluation specifications. The SAC had few 
concerns about the use of the AVP within the clinics, recommending only 
minor modifications to layout, clarity of content, and ease of access for 
minimal disruption to clinic services.  
 
Task 4.3: Draft messages, materials, and protocols 
 
Program drafting followed a stepped sequence. Each component draft built 
upon the iterative review of previous developmental drafts, allowing multiple 
reviews. Strategies were developed for deployment using pre-existing 
delivery platforms: CE provider education on narrated PowerPoint slides on 
HealthStream, Epic cues as programming logic for inclusion in the Epic 
EHR, and patient reminders as text statements formatted for insertion into 
MyChart email announcements (discussed further in Task 5.3). 
 
Task 4.4: Pretest, refine, and produce materials 
 
Each AVP strategy prototype was pretested and refined through an in-
house review and, as amenable, a feasibility pilot test in the 6 advisory 
clinics. 
 
AVP review by the SAC. The AVP project team and SAC previewed AVP 
content and function for consistency with clinic mission and professional 
protocols, and for anomalies such as logical inconsistencies, illegibility, or 
unappealing format. Review was conducted in regular meetings or via e-
mail. Feedback was collated and approved by the project directors prior to 
feasibility testing.  
 
AVP component feasibility testing in advisory clinics. Advisory clinics 
followed protocols to select an AVP champion and rolled out provider 
assessment and feedback over a 2-week period. Champions completed 
logs recording any problems encountered. One champion was interviewed 
at each of the 6 stakeholder clinics. Champions expressed satisfaction with 
the process and their role in distributing and tracking the assessment and 
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feedback reports, and the champions noted that physicians liked the reports 
and were interested in comparing their rates with others. Champion 
recommendations led to protocol adjustments to deliver reports at the 
beginning of the month prior to monthly meetings and to provide a 2-week 
window to return Distribution Logs. 
 
IM STEP 5: IMPLEMENTATION PLAN 
 
Step 5 comprised the description of potential program implementers, 
defining the outcomes and performance objectives for implementation, 
constructing matrices of change objectives for implementation, and 
designing implementation interventions.13  
 
Task 5.1: Identify potential program implementers 
 
The AVP was designed for use by pediatric primary care clinic providers 
and staff.  Potential adopters included the director of the pediatric network, 
clinic directors, providers (pediatricians), and clinic managers. 
 
Task 5.2: State outcomes and performance objectives for 
implementation 
 
Performance objectives for adoption were brainstormed by the project team 
with consideration of the decision-makers in the network and informed by 
the IM framework13 and characteristics for diffusion of innovation.47 
Outcomes included that implementers would recognize a need for the AVP 
and its relative advantage and would make a formal commitment to use 
information technology (IT). Steps for implementation included that the 
clinic network director would assess the need for a program to initiate 
strategies to increase HPV vaccination, review the AVP and its components 
and note objectives and relative advantages for its adoption, obtain 
feedback from clinic staff on potential barriers to/advantages of adopting the 
AVP, and agree to trial the AVP components.  
 
Task 5.3: Construct matrices of change objectives for implementation 
& Task 5.4: Design implementation interventions 
 
Critical opportunities for AVP strategy implementation within the clinics 
were identified using clinic task analysis (previously described). This also 
helped identify existing IT channels by which to deploy the strategies (Table 
6). Matrices categorized objectives for the network CMO to implement the 
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AVP across the network and for the champions to implement the AVP within 
their clinic (Table 7). The AVP is more likely implemented if it is minimally 
disruptive to clinic activities or clinic overhead. Advantages of the AVP 
include its provision of resources and protocols with established feasibility 
and a requirement of only a single investment of resource (mainly staff time 
commitment) to set up an A&F report structure, CE program access, Epic 
cuing setup, and parent reminder message blasts. This upfront commitment 
is offset by significant increases in HPV vaccination rates that approach 
HEDIS benchmarks. 
 
IM STEP 6: EVALUATION PLAN 
 
Step 6 comprised effect and process evaluation questions, developing 
indicators and measures of assessment, and specifying an evaluation 
design. 
 
Task 6.1: Write effect and process evaluation questions 
 
The primary question to be addressed in planning the evaluation of the AVP 
was: Does the use of the AVP within a primary prevention pediatric clinical 
network over a 3-year period increase HPV vaccine initiation and 
completion rates? Stated as an alternative testable empirical hypothesis: A 
clinical network that uses the AVP in the context of their usual clinic 
operations over a 3-year period will demonstrate significantly higher rates 
of HPV vaccine initiation and completion compared to rates prior to AVP 
implementation. Planned process evaluation questions included 
assessment of factors that mediate the success of the AVP as well as 
facilitating its implementation. These include intervention exposure (number 
of A&F reports received, number of providers and staff completing the CE); 
impact on patient-provider communication (change to a bundled vaccine 
recommendation); application of provider cues within the EHR; and 
institution of patient reminders.  
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Table 6. Processes and channels for deployment of AVP strategies 
 
HPV 
STRATEGIES 
IMPLEMENTATION CHANNELS 
PROMOTION DEPLOYMENT (including IT platforms) 
Immunization 
champions  
 
Champions were notified of webinar 
trainings by e-mail. 
• Live training webinars (30 min) using AnyMeeting preceded each 
strategy rollout. System enabling session recording and attendance 
tracking.  
• Champion binders and materials were mailed via the network mail 
system.  
Assessment and 
feedback (A&F) 
report 
 
 
Champions notified clinic personnel in 
regular meetings. 
 
• Reports were generated after accessing data via a Qlikview portal 
within the EHR.  
• Printed reports were delivered to champions via the network mail 
service. Champions distributed reports in clinic meeting or mailboxes 
at their discretion.  
• Champions kept an additional copy of each A&F report in their binder 
and kept a distribution log for tracking.  
Provider 
continued 
education 
CE promotion by:  
• Champions in regular meetings;  
• Promotional flyer included with each 
A&F report;  
• Network CMO in monthly 
newsletters. 
The CE was deployed online through HealthStream, the network’s 
online learning system, and was accessible throughout the study.  
 
Provider 
Reminders 
Champions notified clinic personnel in 
regular meetings. 
Provider reminder best-practice alerts (BPAs) were included in the Epic 
EHR.   
Parent Reminder 
 
Champions were updated in webinar 
and notified clinics in regular 
meetings. 
 
MyChart, a patient facing component of the Epic EHR, sent automated 
content and messaging to all patients listed in an existing Wellness 
Registry (updated nightly) that identified vaccine- and age-eligible 
patients. Quarterly reports tracked the number of reminders sent.  
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Table 7. Matrix of key stakeholders/gatekeepers for implementation 
Performance 
Objectives 
Implementation Stakeholder 
Network CMO Clinic Champion 
AVP Strategy 
To facilitate 
Implementation 
of … 
Knowledge Skills and Self-
efficacy 
Outcome 
Expectations 
Normative 
Beliefs 
Knowledge Skills and Self-
efficacy 
Outcome 
Expectations 
Normative 
Beliefs 
Assessment and 
Feedback (A&F) 
Reports 
K.CMO.A&F: 
Recognize the 
content of A&F 
reports, their 
source data, and 
optimal 
implementation. 
 
SSE.CMO.A&F: 
Demonstrate 
ability to promote 
A&F reports 
across the 
network via 
regional meetings 
and monthly 
newsletters.  
OE.CMO.A&F: 
Expect that A&F 
reports will lead 
to increased 
awareness of 
individual-, 
clinic-, and 
network-level 
vaccine rates. 
NB.CMO.A&F:  
Recognize that 
A&F reports 
can move the 
network’s 
culture toward 
prioritizing HPV 
vaccination.  
K.Champ.A&F: 
Recognize the 
content of A&F 
reports, their 
source data, 
and optimal 
implementation 
in the clinic. 
SSE.Champ.A&F: 
Demonstrate 
ability to promote 
and distribute 
A&F reports via 
clinic meetings 
and/or report 
distribution.  
OE.Champ.A&F: 
Expect that A&F 
reports will lead 
to increased 
awareness of 
individual-, clinic-
, and network-
level vaccine 
rates. 
NB.Champ.A&F:  
Recognize that 
A&F reports can 
move the clinic’s 
culture toward 
prioritizing HPV 
vaccination.  
Continued 
Education (CE) 
K.CMO.A&F: 
Recognize the 
content of CE, 
source data, and 
optimal 
implementation 
in the network. 
SSE.CMO.A&F: 
Demonstrate 
ability to promote 
the CE reports 
across the 
network via 
regional meetings 
and monthly 
newsletters.  
OE.CMO.A&F: 
Expect that CE 
will lead to 
increased HPV-
related 
knowledge and 
skills of network 
personnel. 
NB.CMO.A&F:  
Recognize that 
CE can 
increase the 
network’s 
collective 
awareness and 
skills for HPV 
vaccination.  
K.Champ.A&F: 
Recognize the 
content of CE, 
source data, 
and optimal 
implementation 
in the clinic. 
SSE.Champ.A&F: 
Demonstrate 
ability to promote 
the CE via clinic 
meetings and/or 
flyer distribution 
and ensure 
linkage.  
OE.Champ.A&F: 
Expect that CE 
will lead to 
increased HPV-
related 
knowledge and 
skills of clinic 
personnel. 
NB.Champ.A&F:  
Recognize that 
CE can increase 
the clinics’ 
collective 
awareness and 
skills for HPV 
vaccination. 
Provider Cues 
(PCs) 
K.CMO.A&F: 
Recognize the 
content of PCs, 
their logic, 
source data, and 
optimal 
implementation 
in the network. 
SSE.CMO.A&F: 
Demonstrate 
ability to promote 
PCs across the 
network via 
regional meetings 
and monthly 
newsletters and 
facilitate inclusion 
in EHR..  
OE.CMO.A&F: 
Expect that PCs 
will lead to 
decreased 
missed 
opportunities for 
HPV vaccination 
across the 
network.  
NB.CMO.A&F:  
Recognize that 
PCs are a 
component of 
optimal network 
performance to 
meet national 
HPV 
vaccination 
guidelines.   
K.Champ.A&F: 
Recognize the 
content of PCs, 
source data, 
and optimal 
implementation 
in the clinic. 
SSE.Champ.A&F: 
Demonstrate 
ability to promote 
via clinic 
meetings and/or 
notice distribution.  
OE.Champ.A&F: 
Expect that PCs 
will lead to 
decreased 
missed 
opportunities for 
HPV vaccination 
within the clinic. 
NB.Champ.A&F:  
Recognize that 
PCs are a 
component of 
optimal clinic 
performance to 
meet national 
HPV vaccination 
guidelines.   
Parent 
Reminders 
(PRs) 
K.CMO.A&F: 
Recognize the 
content of PRs, 
their source data, 
layout, and 
optimal 
implementation 
in the network. 
SSE.CMO.A&F: 
Demonstrate 
ability to promote 
PRs across the 
network via 
regional meetings 
and monthly 
newsletters and 
facilitate inclusion 
in MyChart.  
OE.CMO.A&F: 
Expect that PRs 
will lead to 
increased 
appointments 
for HPV 
vaccination 
across the 
network.  
NB.CMO.A&F:  
Recognize that 
PRs are a 
component of 
optimal network 
performance to 
meet national 
HPV 
vaccination 
guidelines.   
K.Champ.A&F: 
Recognize the 
content of PRs, 
source data, 
and optimal 
implementation 
in the clinic. 
SSE.Champ.A&F: 
Demonstrate 
ability to promote 
PRs via clinic 
meetings and/or 
notice distribution.  
OE.Champ.A&F: 
Expect that PRs 
will lead to 
increased 
appointments for 
HPV vaccination 
in the clinic. 
NB.Champ.A&F:  
Recognize that 
PRs are a 
component of 
optimal network 
performance to 
meet national 
HPV vaccination 
guidelines.   
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Task 6.2: Develop indicators and measures for assessment 
 
Evaluation of the AVP focused on collection of centralized data on 
vaccination initiation and completion of the HPV vaccine measured as a 
binary variable (yes/no). Initiation was defined as receiving at least 1 dose 
of the HPV vaccine. Completion was defined as receiving 3 doses in years 
2014 and 2015 and as receiving 2 or 3 doses, depending on age at initiation, 
for 2016-2017. This dosage change corresponded with the updated 
guideline that went into effect in October 2016. Quarterly rates were 
calculated at physician and clinic levels, and annual rates were calculated 
for all clinics combined. AVP data were compared to state-level data from 
the National Immunization Survey (NIS)-Teen for the years 2014, 2015, and 
2016.48 An age group reported by NIS-Teen (13-17 years) was the primary 
comparison with the network in order to evaluate the effect of secular trends.  
 
Planned process measures to assess implementation fidelity were specified 
for each strategy. These included a champion attendance log (to indicate 
attendance at webinars), a provider signoff sheet (to indicate receipt of 
assessment and feedback reports by providers), a back-end data base (to 
record CE use by providers and clinic staff), test results from the network IT 
(to confirm accuracy and ongoing functionality of EHR-based cues), and 
reports on number of vaccination reminders sent to parents of vaccine-
eligible youth. Plans also included records of any reported refusal to adopt 
strategies or barriers to implementation whether organizational or logistic. 
 
Task 6.3: Specify evaluation design 
 
The evaluation design for the AVP was an ecological single-group pre-/post-
test evaluation within the 51-clinic network. A randomized design could not 
be implemented without contamination across study conditions. Further, the 
funding mechanism focused primarily on delivery of services and 
evaluation, and secondarily on research. The systems-based rollout of the 
AVP components took place within all 51 clinics simultaneously. Providers 
and staff in each clinic were invited to complete the baseline survey prior to 
AVP rollout and again at the end of the evaluation period. Cumulated 
vaccination rate data were assessed at baseline and quarterly throughout 
the project in order to give feedback to the physicians and clinics on their 
A&F reports. Clinics then rolled out the AVP strategies according to a 
sequenced timeline. Primary analysis involved comparisons of changes in 
vaccination rates from baseline through 4 years using logistic regression. 
Limitations of the evaluation design are those of internal validity because a 
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quasi experimental design has no randomization or comparison group. 
Although this design can establish a trend, it cannot definitively attribute 
results to the AVP alone. However, it is noteworthy that the AVP was 
associated with significant increases in HPV vaccination initiation and 
completion rates even after considering state-level secular trends based on 
the NIS-Teen.12  
 
DISCUSSION 
 
The AVP is a successful HPV vaccination program designed to address the 
need identified in the Community Guide for implementation of evidence-
based strategies to increase HPV vaccination initiation and completion 
rates and to increase rates to be commensurate with those of Tdap and 
MCV, targeting HEDIS criteria of 80%. It is also responsive to the Healthy 
People 2020 objective to increase the proportion of persons receiving HPV 
vaccination.6  
 
The IM framework was used to design the AVP due to its potential utility in 
developing multilevel systems-based approaches. Advantages of the 
framework include the imposition of a systematic approach; thoroughness 
in detailing needs and solutions informed by theoretical and empirical 
literature; encouraging critical thinking regarding implementation, 
evaluation, and dissemination; and ensuring that priority populations were 
consulted throughout. The IM framework is built to accommodate the use 
of  theories designed to inform development of behavioral change 
interventions (eg, Social Cognitive Theory,44 Theory of Reasoned Action,45 
Health Belief Model46) as well as those designed to inform the development 
and packaging of implementation strategies that facilitate the use of 
interventions within clinics (eg, Diffusion of Innovation47.   
Consolidated Framework for Implementation Research).48,49 
 
The resulting components of AVP are theory- and evidence-based, 
packaged into a product that can be integrated into an existing clinic 
network’s workflow and technology system. Though many of the 
components found in this study have been used previously, they are 
independently insufficient; combining them with other evidence-based 
components and a novel parent educational app reflects the next generation 
of interventions to increase HPV vaccine rates. 
 
Other interventions focused on HPV vaccine rates have been effective to a 
varying extent. Though many interventions have tested the efficacy and 
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effectiveness of one component or one level of an HPV intervention,9 this is 
the first intervention to our knowledge to use IM to develop a successful 
multilevel intervention focused on increasing HPV vaccine rates in a 
pediatric clinic setting. To date, there is a lack of ubiquitous adoption and 
implementation of evidence-based practices. The current study targets the 
provider and clinic levels to influence behavioral and system-level changes.  
 
The current study has several strengths. First, a comprehensive team of 
experts and potential participants on the provider level developed the 
intervention using dynamic feedback from those who could benefit most 
from the intervention’s components. Second, the intervention received 
strong “buy-in” from the participating pediatric network, which provides 
health care for a significant portion of the city’s pediatric care population. 
Third, the intervention was developed to address needs at organizational, 
provider, and patient levels, which contribute to a higher likelihood of  
behavior change than focusing on one level alone.9,50  
 
Findings need interpretation in light of study limitations. The generalizability 
of the AVP is unknown because it was developed with the participation of 
one pediatric network and limited to a single geographic urban area. 
However, by utilizing one of the largest pediatric networks in the U.S., 
including 51 clinics of various size, this study helps build evidence of 
feasibility and acceptability across diverse clinic settings. Further, while the 
evaluation of the AVP suggests success in terms of increasing HPV vaccine 
rates, the relative efficacy and impact of each individual component on the 
outcomes of our intervention are unclear. 
 
The AVP development presented here represents one case study 
application for a systems-based intervention in a clinical context. In this 
capacity, it provides a guide for future development in analogous domains, 
populations, and applications. However, in practice the degree of fidelity to 
IM core processes varied with each development task. The formality of 
posing questions, brainstorming answers, reviewing findings from published 
research, accessing and using theory, identifying and addressing the need 
for new research, and formulating the working list of answers varied among 
components of A&F, CE, cues, and reminders dependent on project 
constraints and existing practices. Also, the evaluation plan was limited to 
the period of study and did not include an assessment of sustainability in 
the long term. IM was conducive to providing an innovative multicomponent 
approach to implementing evidence-based strategies within primary care 
pediatric clinics. By providing evidence-based tools and procedures for 
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identifying and assisting clinics to increase HPV vaccination rates, this study 
contributes to the national goal. 
 
CONCLUSION 
 
Limited impact of current interventions to increase use of HPV vaccine 
among adolescents represents a missed opportunity to prevent multiple 
types of HPV-related cancer. IM provided a framework to develop a 
multilevel, multicomponent intervention aimed at clinic system, providers, 
and parents to promote implementation of evidence-based strategies to 
increase HPV vaccine uptake and completion among adolescents ages 11-
17. The AVP’s feasibility for clinic use and efficacy in increasing HPV 
vaccination in a large pediatric clinic network in the southwestern United 
States is testament to the utility of IM as a framework for development of 
systems-based interventions.  
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Future directions 
 
Future directions for the AVP include determining overall initiation and 
completion outcomes and testing dissemination and implementation for use 
among other clinic networks. The AVP is currently being expanded to a 
smaller pediatric clinic network in the same state. Of note, members of the 
original clinic network in this study have requested assistance with 
permanent adoption of AVP components for sustainability within the clinics. 
This interest in the AVP suggests that broader dissemination is indicated.    
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